Virus freeze-drying protective agent, Japanese encephalitis virus freeze-drying preparation and preparation method of Japanese encephalitis virus freeze-drying preparation
By using viral lyophilized protective agents composed of skim milk, amino acid substances and polylactic acid-polyvinylpyrrolidone, the problem of high storage cost and short time of type B encephalitis virus is solved, and the titer after virus lyophilization is achieved Stability and activity are maintained, meeting the needs of long-term storage.
Patent Information
- Application Number
- CN202411343710.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-08
AI Technical Summary
In the prior art, the liquid cryopreservation cost of type B encephalitis virus is high and the storage time is short, resulting in a decrease in the titer of the Japanese encephalitis virus and cannot meet the storage requirements of 2 years or more.
Virus lyophilized protective agent composed of skim milk, amino acid substances and polylactic acid-polyvinyl pyrrolidone, etc. is prepared by forming a protective layer, stabilizing the pH environment and hydrogen bonding, maintaining the integrity and activity of the virus, and preparing the B-type brain lyophilized preparation of inflammation virus.
It effectively reduces the cost of virus preservation and extends the storage time of virus. The titer of the Japanese encephalovirus is basically unchanged after lyophilization, maintaining its infectivity and activity.
Smart Images

Figure BDA0005060390920000051 
Figure BDA0005060390920000052 
Figure BDA0005060390920000071
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of biological preparations, and in particular to a virus freeze-dried protective agent, a Japanese encephalitis virus freeze-dried preparation and a preparation method thereof. Background Art
[0002] Japanese Encephalitis Virus (JEV), also known as Japanese encephalitis virus, is the pathogenic virus of epidemic Japanese encephalitis. When a person is infected with Japanese encephalitis virus, the virus will proliferate in phagocytes such as vascular endothelial cells, lymph nodes, liver, and spleen, and reach the brain through the blood circulation, thereby causing inflammation of the meninges and brain tissue, degeneration and necrosis of neuronal cells, softening of brain tissue and other diseases.
[0003] At present, vaccination with inactivated Japanese encephalitis vaccine is the main means of preventing Japanese encephalitis virus infection. In the production process of inactivated Japanese encephalitis vaccine, the main way to preserve Japanese encephalitis virus strains is liquid freezing, that is, by mixing Japanese encephalitis virus strains with protective agents and placing them in low-temperature equipment for long-term storage. Although the above method can ensure the activity and infectivity of Japanese encephalitis virus, this method requires long-term use of special low-temperature equipment, such as ultra-low temperature refrigerators or liquid nitrogen tanks, so the storage cost is relatively high; in addition, when the Japanese encephalitis virus is stored for 1 year using the above liquid freezing method, the titer of the Japanese encephalitis virus will show a significant downward trend, which cannot meet the storage requirements of 2 years or more.
[0004] Therefore, reducing the storage cost of JE virus and extending its storage time have become the main research directions at present. Summary of the invention
[0005] In order to overcome the problems of high storage cost, short storage time and decreased titer of Japanese encephalitis virus in the prior art, the present application provides a virus lyophilization protectant, a Japanese encephalitis virus lyophilized preparation and a preparation method thereof.
[0006] In the first aspect, the present application provides a virus freeze-dried protective agent, which adopts the following technical solution: A virus freeze-dried protective agent comprises the following components: 1-5% skim milk, 5-10% sorbitol, 0.2-1.2% arginine, 0.4-1.2% sodium glutamate and 0.1-0.8% polylactic acid-polyvinyl pyrrolidone, and the balance is water.
[0007] The present application uses skim milk, amino acid substances and polylactic acid-polyvinyl pyrrolidone to prepare a virus freeze-drying protective agent, wherein skim milk is a macromolecular substance on the one hand, which can form a freeze-drying scaffold during the freeze-drying process, and this framework can enhance the protection of viruses; on the other hand, skim milk can form weak glass, which has a good protective effect on viruses during the freeze-drying process. Sodium glutamate and arginine can inhibit slight changes in the pH of the system, thereby preventing protein denaturation. Sorbitol has multiple hydroxyl groups, which can replace water molecules and phosphate groups in cell membrane phospholipids or form hydrogen bonds with protein polar groups during the freeze-drying process to protect the integrity of cell membrane and protein structure and function. Polylactic acid-polyvinyl pyrrolidone can bind to specific parts of virus particles, stabilize the conformation of the virus, and prevent irreversible conformational changes in the virus during freeze-drying; and polylactic acid-polyvinyl pyrrolidone can also form a protective layer on the surface of cell viruses to avoid damage to the virus during freeze-drying and maintain the integrity and activity of the virus; in addition, during the rehydration of the freeze-dried preparation of Japanese encephalitis virus, polylactic acid-polyvinyl pyrrolidone can quickly absorb and retain moisture, provide a moist environment for the virus, and help the virus quickly restore its infectivity and activity. Therefore, the virus freeze-dried protective agent provided in this application acts on the freeze-drying process of the virus by forming a protective layer on the surface of the virus particles, stabilizing the pH environment, hydrogen bonding, and maintaining the conformation of the virus, etc., to ensure that the virus can maintain its integrity, infectivity and activity after freeze-drying.
[0008] Optionally, the virus freeze-dried protective agent comprises the following components: 2-4% skim milk, 5-10% sorbitol, 0.2-1.2% arginine, 0.4-1.2% sodium glutamate and 0.2-0.6% polylactic acid-polyvinyl pyrrolidone, and the balance is water.
[0009] In some embodiments, the weight portions of the skim milk can be 1-2 portions, 1-3 portions, 1-4 portions, 1-5 portions, 2-3 portions, 2-4 portions, 2-5 portions, 3-4 portions, 3-5 portions, or 4-5 portions.
[0010] In a specific embodiment, the weight portion of the skim milk can also be 1 part, 2 parts, 3 parts, 4 parts Or 5 servings.
[0011] In some embodiments, the weight proportion of the polylactic acid-polyvinyl pyrrolidone may be 0.1-0.2, 1-0.4, 0.1-0.6, 0.1-0.8, 0.2-0.4, 0.2-0.6, 0.2-0.8, 0.4-0.6, 0.4-0.8 or 0.6-0.8.
[0012] In a specific embodiment, the weight portion of the polylactic acid-polyvinyl pyrrolidone can also be 0.1 part, 0.2 part, 0.4 part, 0.6 part or 0.8 part.
[0013] Optionally, the virus freeze-dried protective agent comprises the following components: 3% skim milk, 5% sorbitol, 1% arginine, 1% sodium glutamate and 0.4% polylactic acid-polyvinyl pyrrolidone, and the balance is water.
[0014] Optionally, the molecular weight of the polylactic acid-polyvinyl pyrrolidone is 8k-20kg / mol.
[0015] In some embodiments, the molecular weight of the polylactic acid-polyvinyl pyrrolidone can be 8k-10kg / mol, 8-15kg / mol, 8-18kg / mol, 8-20kg / mol, 10-15kg / mol, 10-18kg / mol, 10-20kg / mol, 15-18kg / mol, 15-20kg / mol or 18-20kg / mol.
[0016] In a specific embodiment, the molecular weight of the polylactic acid-polyvinyl pyrrolidone may also be 8 kg / mol, 10 kg / mol, 15 kg / mol, 18 kg / mol or 20 kg / mol.
[0017] Optionally, the molecular weight of the polylactic acid-polyvinyl pyrrolidone is 10k-18k g / mol.
[0018] In the present application, the molecular weight of polylactic acid-polyvinyl pyrrolidone affects the protective effect of the virus freeze-drying protective agent on Japanese encephalitis virus. Through experimental research, it was found that by further controlling the molecular weight of polylactic acid-polyvinyl pyrrolidone within the above range, the obtained virus freeze-drying protective agent has a better protective effect on Japanese encephalitis virus, and the titer of Japanese encephalitis virus before and after freeze-drying is basically unchanged.
[0019] Optionally, in the polylactic acid-polyvinyl pyrrolidone, the molar ratio of lactic acid to N-vinyl pyrrolidone is (65-75): (25-35).
[0020] In a second aspect, the present application provides an application of a virus freeze-dried protective agent in the preparation of a virus freeze-dried product.
[0021] In a third aspect, the present application provides a Japanese encephalitis virus lyophilized preparation comprising Japanese encephalitis virus and a viral lyophilization protectant.
[0022] Optionally, the method for preparing the Japanese encephalitis virus freeze-dried preparation comprises the following steps: mixing the Japanese encephalitis virus harvest liquid with the virus freeze-drying protective agent in a volume ratio of 4: (0.8-1.2), and performing vacuum freeze drying to obtain the Japanese encephalitis virus freeze-dried preparation.
[0023] Optionally, the vacuum freeze-drying procedure is: first pre-freeze at -42±5°C for 200-250 minutes, then increase the temperature to -3±2°C within 120 minutes, and dry at the above temperature for 13-15 hours; then increase the temperature to 28±2°C within 190 minutes, and dry at the above temperature for a second time for 8-9 hours.
[0024] In summary, this application has the following beneficial effects: 1. The present application uses skimmed milk, amino acid substances and polylactic acid-polyvinyl pyrrolidone to prepare a virus freeze-drying protectant, which acts on the freeze-drying process of the virus by forming a protective layer on the surface of virus particles, stabilizing the pH environment, hydrogen bonding and maintaining the virus conformation, etc., to ensure that the virus can maintain its integrity, infectivity and activity after freeze-drying.
[0025] 2. The present application further uses polylactic acid-polyvinyl pyrrolidone with a molecular weight of 10-18k to prepare a virus freeze-dried protective agent, and by controlling the addition amount of polylactic acid-polyvinyl pyrrolidone within the range of 0.2-0.6 parts, the obtained virus freeze-dried protective agent has a better protective effect on Japanese encephalitis virus, and the titer of Japanese encephalitis virus before and after freeze-drying is basically unchanged. DETAILED DESCRIPTION
[0026] The present application provides a virus freeze-dried protective agent, comprising the following components: 1-5% skim milk, 5-10% sorbitol, 0.2-1.2% arginine, 0.4-1.2% sodium glutamate and 0.1-0.8% polylactic acid-polyvinyl pyrrolidone, and the balance is water; further, the virus freeze-dried protective agent comprises the following components: 2-4% skim milk, 5-10% sorbitol, 0.2-1.2% arginine, 0.4-1.2% sodium glutamate and 0.2-0.6% polylactic acid-polyvinyl pyrrolidone, and the balance is water.
[0027] Among them, in the polylactic acid-polyvinyl pyrrolidone, the molar ratio of lactic acid to N-vinyl pyrrolidone is (65-75): (25-35); the molecular weight of the polylactic acid-polyvinyl pyrrolidone is 8k-20k g / mol; further, the molecular weight of the polylactic acid-polyvinyl pyrrolidone is 10k-18k g / mol.
[0028] The present application provides a freeze-dried preparation of Japanese encephalitis virus, the preparation method of which comprises the following steps: (1) Preparation of Japanese encephalitis virus harvest fluid.
[0029] (2) mixing the Japanese encephalitis virus harvest solution and the virus freeze-dried protective agent in a volume ratio of 4: (0.8-1.2) to obtain a vaccine mixture; (3) The vaccine mixture is loaded into a vial and placed in a box at room temperature. First, it is pre-frozen at -42±5°C for 200-250 minutes. Then, the temperature is raised to -3±2°C within 120 minutes, and the vial is dried at the above temperature for 13-15 hours. Then, the temperature is raised to 28±2°C within 190 minutes, and the vial is dried at the above temperature for a second time for 8-9 hours. After freeze-drying, a freeze-dried preparation of Japanese encephalitis virus is obtained.
[0030] In the present application, the Vero cell batch number is Vero201028, purchased from ATCC; the Japanese encephalitis virus P3 strain comes from Beijing Institute of Inspection and Quarantine; skim milk is purchased from BD Company of the United States; sorbitol is D-sorbitol; polylactic acid-polyvinyl pyrrolidone is customized from Hangzhou Xinqiao Biotechnology Co., Ltd.; the remaining raw materials, reagents, solvents, etc. of the present application can also be obtained through commercial purchase.
[0031] The present application is further described in detail below in combination with preparation examples, embodiments, and performance testing experiments.
[0032] Preparation Example 1-5 Preparation Examples 1-5 each provide a virus freeze-dried protective agent.
[0033] The difference between the above preparation examples is that the amount of skim milk added to the virus freeze-drying protective agent is shown in Table 1 below.
[0034] The preparation method of the virus freeze-dried protective agent provided in Preparation Example 1-5 comprises the following steps: first, dissolve skim milk in 100 g of water, treat it at a high temperature of 110-120°C for 20±5 min, cool it to room temperature, add sorbitol 5 g, arginine 1 g, sodium glutamate 1 g, polylactic acid-polyvinyl pyrrolidone (molecular weight is 15 kg / mol, and the molar ratio of lactic acid to N-vinyl pyrrolidone is 70:30) 0.1 g to dissolve, and filter it with a 0.22 μm filter to obtain a virus freeze-dried protective agent.
[0035] Table 1 The amount of skim milk added to the virus freeze-dried protective agent provided in Preparation Example 1-5 Preparation Example Amount of skim milk added (g) 1 1 2 2 3 3 4 4 5 5 Preparation Example 6-8 Preparation Examples 6-9 each provide a virus freeze-dried protective agent.
[0036] The difference between the above preparation example and preparation example 3 is that the amount of polylactic acid-polyvinyl pyrrolidone added is as shown in Table 2 below.
[0037] Table 2 Addition amount of polylactic acid-polyvinyl pyrrolidone in the virus freeze-drying protective agent provided in Preparation Examples 6-9 Preparation Example 10-13 Preparation Examples 10-13 each provide a virus freeze-dried protective agent.
[0038] The difference between the above preparation example and preparation example 7 is that the molecular weight of polylactic acid-polyvinyl pyrrolidone is shown in Table 3 below.
[0039] Table 3 Molecular weight of polylactic acid-polyvinyl pyrrolidone used in Preparation Examples 7 and 10-13 Comparative Preparation Example 1 Comparative Preparation Example 1 provides a virus freeze-dried protective agent.
[0040] The difference between the above comparative preparation example and preparation example 3 is that arginine is replaced by glycine.
[0041] Comparative Preparation Example 2 Comparative Preparation Example 2 provides a virus freeze-dried protective agent.
[0042] The difference between the comparative preparation example and preparation example 3 is that the amount of polylactic acid-polyvinyl pyrrolidone added to the virus freeze-drying protective agent is 0 g.
[0043] Comparative Preparation Example 3 Comparative Preparation Example 3 provides a virus freeze-dried protective agent.
[0044] The difference between the comparative preparation example and preparation example 3 is that the amount of polylactic acid-polyvinyl pyrrolidone added to the virus freeze-drying protective agent is 1 g.
[0045] Examples 1-13 Examples 1-13 each provide a freeze-dried preparation of Japanese encephalitis virus.
[0046] The difference between the above embodiments is that the virus lyophilization protectants in the Japanese encephalitis virus lyophilized preparations are derived from Preparation Examples 1-13 respectively.
[0047] The preparation method of the freeze-dried preparation of Japanese encephalitis virus provided in Examples 1-13 comprises the following steps: (1) Preparation of Japanese encephalitis virus harvest fluid: Vero cells were centrifuged at 175 cm 2The cells were revived in square bottles and inoculated into 850 roller bottles at a subculture ratio of 1:10. When the number of roller bottles was sufficient for the inoculation experiment, well-grown Vero monolayer cells were taken, the culture medium was discarded, and the Japanese encephalitis virus P3 strain was inoculated at an MOI of 1:500. The cells were fully adsorbed at 33°C and 5% CO2 for about 1 hour, gently shaken once every 30 minutes, supplemented with virus maintenance medium (M199 culture medium), and cultured in a 33°C 5% CO2 incubator; the cell cytopathic effect was observed every day, the virus maintenance medium was replaced on the second day, and then the Japanese encephalitis virus harvest fluid was harvested when the cell cytopathic effect reached more than 80%.
[0048] (2) mixing the Japanese encephalitis virus harvest solution and the virus freeze-dried protective agent in a volume ratio of 4:1 to obtain a vaccine mixture; (3) The vaccine mixture is loaded into a vial and placed in a container at room temperature. First, it is pre-frozen at -42°C for 210 minutes, then the temperature is raised to -3°C within 120 minutes, and the vial is dried at the above temperature for 14 hours; then the temperature is raised to 28°C within 190 minutes, and the vial is dried at the above temperature for a second time for 8 hours and 40 minutes. After freeze-drying, a freeze-dried preparation of Japanese encephalitis virus is obtained.
[0049] Comparative Examples 1-3 Comparative Examples 1-3 each provide a freeze-dried preparation of Japanese encephalitis virus.
[0050] The difference between the comparative example and the embodiment is that the virus lyophilization protective agent in the Japanese encephalitis virus lyophilized preparation is derived from comparative preparation examples 1-3 respectively.
[0051] Performance testing The titer of the freeze-dried Japanese encephalitis virus preparations provided in Examples 1-13 and Comparative Examples 1-3 was tested, and the results are shown in Table 4 below.
[0052] Experimental method: First, freeze-dried preparations of Japanese encephalitis virus were prepared according to Examples 1-13 and Comparative Examples 1-3, and three samples were prepared in parallel for each example, one of which was directly tested for titer after preparation; the other two were stored at 24°C for 12 months and -70°C for 24 months, and the titer was tested again after the time limit.
[0053] The titer detection method is as follows: add sterile injection water to the freeze-dried preparation of Japanese encephalitis virus to dissolve it, filter the dissolved solution through a 0.22μm filter membrane, and then use the mouse brain titration method to detect the titer to obtain the virus titer value (LgLD50); and calculate the titer change rate of each preparation before and after freeze-drying, and the calculation formula is as follows: Titer change rate before and after freeze-drying (%) = (T1-T2) / T1×100% Wherein, T1 is the titer of the vaccine mixture, and T2 is the titer of the freeze-dried preparation of Japanese encephalitis virus.
[0054] Note: The Japanese encephalitis virus harvest solution used in each embodiment and comparative example is the same, and the initial titer of the vaccine mixture is 8.635lgLD50.
[0055] Table 4 Titer test results of Japanese encephalitis virus freeze-dried preparations According to the test results of Table 4, the titer of the lyophilized preparation of Japanese encephalitis virus provided by Example 1-13 is 8.245-8.620, and the titer decrease rate before and after lyophilization is 0.17-4.52% (<5%), and the titer decrease is not significant after being stored at 4°C for 12 months and -70°C for 24 months; while the titer of the lyophilized preparation of Japanese encephalitis virus provided by Comparative Example 1-3 is 7.693-7.895, and the titer decrease rate before and after lyophilization is 8.57-10.91% (>5%), and the titer decreases significantly after being stored at 4°C for 12 months and -70°C for 24 months. Therefore, it is explained that the virus lyophilization protective agent provided by Preparation Examples 1-13 of the present application has a good protective effect on Japanese encephalitis virus, can keep the activity and virulence of Japanese encephalitis virus during the lyophilization process, and the storage time of Japanese encephalitis virus is long.
[0056] The test results of Examples 1-5 show that as the amount of skim milk added increases, the titer of the freeze-dried preparation of Japanese encephalitis virus first increases and then remains basically unchanged; further comparison shows that when the amount of skim milk powder added in Example 1 is 1 part, the titer of the freeze-dried preparation of Japanese encephalitis virus obtained is 8.245, and the titer reduction rate before and after freeze-drying is 4.52%; and when the amount of skim milk powder added in Examples 2-5 is controlled to 2-5 parts, the titer of the freeze-dried preparation of Japanese encephalitis virus obtained is 8.364-8.442, and the titer reduction rate before and after freeze-drying is 2.24-3.14%. Therefore, considering the comprehensive economic cost, the present application further controls the amount of skim milk powder added to 2-4 parts, and the obtained virus freeze-dried protective agent has a better protective effect on Japanese encephalitis virus.
[0057] It can be seen from the test results of Example 3 and Examples 6-9 that with the increase in the amount of polylactic acid-polyvinyl pyrrolidone added, the titer of the Japanese encephalitis virus freeze-dried preparation first increased and then decreased; further comparison found that when the amount of polylactic acid-polyvinyl pyrrolidone added in Example 3 was 0.1 parts, the titer of the Japanese encephalitis virus freeze-dried preparation obtained was 8.442, and the titer decrease rate before and after freeze-drying was 2.24%; when the amount of polylactic acid-polyvinyl pyrrolidone added in Example 9 was 0.8 parts, the titer of the Japanese encephalitis virus freeze-dried preparation obtained was 8.425, and the titer decrease rate before and after freeze-drying was 2.43%; and when the amount of skim milk powder added in Examples 6-8 was controlled at 0.2-0.6 parts, the titer of the Japanese encephalitis virus freeze-dried preparation obtained was 8.518-8.617, and the titer decrease rate before and after freeze-drying was 0.21-1.35% (<2%). Therefore, it is explained that the application further controls the addition amount of polylactic acid-polyvinyl pyrrolidone within the range of 0.2-0.6 parts, and the obtained virus freeze-dried protective agent has a better protective effect on Japanese encephalitis virus.
[0058] The test results of Examples 7 and 10-13 show that the molecular weight of polylactic acid-polyvinyl pyrrolidone will affect the protective effect of the virus freeze-dried protective agent on Japanese encephalitis virus. Example 10 uses polylactic acid-polyvinyl pyrrolidone with a molecular weight of 8k, and the titer of the Japanese encephalitis virus freeze-dried preparation obtained is 8.483, and the titer decrease rate before and after freeze-drying is 1.76%; Example 13 uses polylactic acid-polyvinyl pyrrolidone with a molecular weight of 20k, and the titer of the Japanese encephalitis virus freeze-dried preparation obtained is 8.496, and the titer decrease rate before and after freeze-drying is 1.61%; and Examples 7 and 11-12 use polylactic acid-polyvinyl pyrrolidone with a molecular weight of 10-18k, and the titer of the Japanese encephalitis virus freeze-dried preparation obtained is 8.594-8.620, and the titer decrease rate before and after freeze-drying is 0.17-0.47% (<1%). Therefore, it is shown that the present application further uses polylactic acid-polyvinyl pyrrolidone with a molecular weight of 10-18k to prepare a virus freeze-dried protective agent, and the obtained virus freeze-dried protective agent has a better protective effect on Japanese encephalitis virus, and the titer of Japanese encephalitis virus before and after freeze-drying does not change substantially.
[0059] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A virus freeze-drying protective agent, characterized in that: The invention comprises the following components: 1-5% of skim milk, 5-10% of sorbitol, 0.2-1.2% of arginine, 0.4-1.2% of sodium glutamate and 0.1-0.8% of polylactic acid-polyvinyl pyrrolidone, and the balance is water.
2. The virus freeze-dried protective agent according to claim 1, characterized in that The invention comprises the following components: 2-4% skim milk, 5-10% sorbitol, 0.2-1.2% arginine, 0.4-1.2% sodium glutamate and 0.2-0.6% polylactic acid-polyvinyl pyrrolidone, and the balance is water.
3. The virus freeze-dried protective agent according to claim 1, characterized in that The invention comprises the following components: 3% skim milk, 5% sorbitol, 1% arginine, 1% sodium glutamate and 0.4% polylactic acid-polyvinyl pyrrolidone, and the balance is water.
4. The virus freeze-dried protective agent according to any one of claims 1 to 3, characterized in that The molecular weight of the polylactic acid-polyvinyl pyrrolidone is 8k-20k g / mol.
5. The virus freeze-dried protective agent according to claim 1, characterized in that The molecular weight of the polylactic acid-polyvinyl pyrrolidone is 10k-18k g / mol.
6. The virus freeze-dried protective agent according to claim 1, characterized in that In the polylactic acid-polyvinyl pyrrolidone, the molar ratio of lactic acid to N-vinyl pyrrolidone is (65-75): (25-35).
7. Use of the virus freeze-drying protectant according to any one of claims 1 to 6 in the preparation of virus freeze-dried products.
8. A freeze-dried preparation of Japanese encephalitis virus, characterized in that: The invention comprises Japanese encephalitis virus and the virus freeze-dried protective agent according to any one of claims 1 to 6.
9. The method for preparing the freeze-dried preparation of Japanese encephalitis virus according to claim 8, characterized in that: The following steps are involved: The Japanese encephalitis virus harvest solution and the virus freeze-drying protective agent are mixed in a volume ratio of 4: (0.8-1.2), and the mixture is subjected to vacuum freeze-drying to obtain a Japanese encephalitis virus freeze-dried preparation.
10. The method for preparing the freeze-dried preparation of Japanese encephalitis virus according to claim 9, characterized in that: The vacuum freeze-drying procedure is: first pre-freeze at -42±5°C for 200-250 minutes, then increase the temperature to -3±2°C within 120 minutes, and dry at the above temperature for 13-15 hours; then increase the temperature to 28±2°C within 190 minutes, and dry at the above temperature for a second time for 8-9 hours.
